Endo's Generic OxyContin To Launch Following Patent Invalidation
This article was originally published in The Pink Sheet Daily
Executive Summary
D.C. federal appeals court upholds a ruling invalidating Purdue's patents due to inequitable conduct by the brand company. Endo says it holds 180-day exclusivity on three of four doses of oxycodone extended-release. Purdue plans to seek en banc review of the appellate panel's decision.
You may also be interested in...
OxyContin Will Face Fewer Generics Following Patent Infringement Settlement
As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.
OxyContin Will Face Fewer Generics Following Patent Infringement Settlement
As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.
Risky Business: Appellate Decision Returns Endo's Generic OxyContin Case To Trial Court
A federal appeals court affirms a trial court decision that Endo's product would infringe Purdue's patents.